Table 1 Summary of the study characteristics
Study, Year | Summary | Number of patients with pre- and post-TAVR CMR | Follow-up (months) | Age | Male (%) | Diabetes n (%) | Previous MI n (%) | Baseline LVEF (%) | LVEF (%) at Late Follow-up | Valve Prosthesis | Early post-TAVR CMR findings (within 7 days post-TAVR) | Excluded patients, Explanation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gastl M, et al. 2018 [25] | 43 patients with severe AS underwent TAVR. | 29 | 6 | 81.9 ± 4.9 | 43% | 12 (28) | 5 (12) | 58.1 ± 16.1 | 62.9 ± 10.4 | CoreValve, Edwards Sapien | – | 14 patients (poor image quality, left bundle branch block) |
aMusa TA, et al. 2018 [10] | 59 patients with severe AS underwent TAVR with either CoreValve (n = 27) or Lotus (n = 32). | 19 | 6 | 79.6 ± 6.3 | 63% | 2 (11) | 3 (16) | 56.2 ± 12.8 | 56.4 ± 8.6 | CoreValve | CMR findings at median 4 days: No significant changes to LVEDVi and LVEF (p = 0.46 and p = 0.84) Significant reduction of LVMi (75.4 ± 15.0 vs. 65.8 ± 13.6 g/m2, p < 0.001) | 15 patients (Death, PPM, withdrawal) |
25 | 6 | 78.6 ± 8.7 | 56% | 5 (20) | 6 (24) | 51.0 ± 19.0 | 54.1 ± 9.3 | Lotus | No significant changes to LVEDVi and LVEF (p = 0.55 and p = 0.49) No significant changes to LVMi (70.8 ± 25.0 vs 69.6 ± 16.2 g/m2, p = 0.81) | |||
Dobson LE, et al. 2017 [9] | 88 patients with severe AS underwent TAVR. Ultimately, 24 patients with new left bundle branch block who were matched with 24 patients with a narrow post-procedure QRS were assessed. | 24 | 6 | 79.6 ± 9.6 | 54% | 2 (8.3) | 2 (8.3) | 56.6 ± 10.5 | 54.4 ± 9.3 | CoreValve, Lotus | – | 40 patients were excluded for various reasons, (Death, PPM, withdrawal, right bundle branch block, post-procedural myocardial infarction in 23 patients; and an additional 17 because they were not matched to a control group. CMR results of those patients were not presented) |
24 | 6 | 80.5 ± 6.2 | 54% | 5 (20.8) | 5 (20.8) | 54.1 ± 11.5 | 58.7 ± 9 | |||||
Nucifora G, et al. 2017 [26] | 59 patients with severe AS underwent either TAVR (n = 35) or SAVR (n = 24). For the current manuscript, only the TAVR cohort was considered. | 17 | 15 ± 4 | 85 ± 6 | 63% | – | NA | 68 ± 16 | 70 ± 14 | Edwards Sapien XT | CMR findings at 4.7 ± 4 days: No significant changes to LVEF, and LVMi (p = 0.63 and p = 0.27) | 18 patients (not mentioned) |
aMusa TA, et al. 2016 [11] | 167 patients with severe AS underwent TAVR (n = 101), or SAVR (n = 66). For the current manuscript, only the TAVR cohort was considered. | 56 | 6 | 80.4 ± 6.6 | 57% | 11 (20) | 11 (20) | 52 ± 13 | 53 ± 11 | CoreValve, Lotus | – | 45 patients (Death, PPM, withdrawal, valvuloplasty, medical therapy, claustrophobia) |
Fairbairn TA, et al.2013 [27] | 77 patients with severe AS underwent TAVR (n = 50) or SAVR (n = 27). For the current manuscript, only the TAVR cohort was considered. | 25 | 6 | 80 ± 6 | 56% | 7 (28) | 5 (20) | 52 ± 12 | 56 ± 10 | CoreValve | – | 25 patients (Death, PPM, withdrawal, valvuloplasty, medical therapy, claustrophobia) |
La Manna A, et al. 2013 [28] | 39 patients with severe AS underwent TAVR | 27 | 6 | 80.7 ± 5.2 | 37% | 4 (14.8) | 7 (25.9) | 61.5 ± 14.5 | 65.1 ± 7.2 | CoreValve, Edwards-Sapien | – | 12 patients (Death, PPM, withdrawal) |
Uddin A, et al. 2013 (abstract) [24] | 25 patients with severe AS had TAVR and underwent CMR. | 25 | 6 | 80.6 ± 6.6 | 56% | – | – | 52.1 ± 11.8 | 55.9 ± 9.6 | CoreValve | – | – |
Gruenig S, et al. 2013 (abstract) [30] | 20 patients with severe AS underwent TAVR and had CMR. | 20 | 6 | 83.6 ± 10.5 | – | – | – | 55 ± 21 | 63 ± 39 | CoreValve, Edwards-Sapien | – | – |
Richardson J, et al. 2012 (abstract) [31] | 14 patients with severe AS underwent TAVR and had CMR. | 14 | 10 | – | – | – | – | 54 ± 4 | 57 ± 5 | CoreValve, Edwards-Sapien | – | – |